Have your own idea? Try our Stock Screener
The Clinical Research and Equipment industry is up 8.6% in the last week, with WuXi Biologics (Cayman) up 12%. Meanwhile, Genscript Biotech actually underperformed within the industry, shrinking 9.2% in the last week. This means that the industry has gained 57% over the past year. As for the next few years, earnings are expected to grow by 33% per annum.
Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Wed, 19 Mar 2025 | HK$215.7b | HK$32.7b | -HK$202,654,047.15 | 46.5x | -1064.6x | 6.6x |
Fri, 14 Feb 2025 | HK$171.6b | HK$35.8b | -HK$1,060,919,669.78 | 52.7x | -161.7x | 4.8x |
Sun, 12 Jan 2025 | HK$151.3b | HK$35.6b | -HK$1,062,130,458.29 | 62.6x | -142.5x | 4.2x |
Tue, 10 Dec 2024 | HK$165.1b | HK$35.8b | -HK$1,057,872,578.99 | 59.3x | -156.1x | 4.6x |
Thu, 07 Nov 2024 | HK$156.8b | HK$35.5b | -HK$665,828,377.13 | 40.1x | -235.5x | 4.4x |
Sat, 05 Oct 2024 | HK$195.3b | HK$35.9b | -HK$652,704,448.85 | 44.4x | -299.2x | 5.4x |
Mon, 02 Sep 2024 | HK$127.6b | HK$35.9b | -HK$659,504,477.72 | 25.6x | -193.4x | 3.6x |
Wed, 31 Jul 2024 | HK$90.2b | HK$33.5b | HK$3.1b | 17x | 29.2x | 2.7x |
Fri, 28 Jun 2024 | HK$90.2b | HK$33.4b | HK$3.1b | 19.6x | 29.4x | 2.7x |
Sun, 26 May 2024 | HK$96.4b | HK$33.5b | HK$3.1b | 29.5x | 31.2x | 2.9x |
Tue, 23 Apr 2024 | HK$99.4b | HK$33.6b | HK$3.1b | 31.3x | 32.1x | 3x |
Thu, 21 Mar 2024 | HK$116.5b | HK$33.3b | HK$3.7b | 49.9x | 31.7x | 3.5x |
Sat, 17 Feb 2024 | HK$125.1b | HK$32.5b | HK$3.0b | 46.9x | 41.4x | 3.8x |
Mon, 15 Jan 2024 | HK$206.0b | HK$32.4b | HK$3.0b | 85.9x | 68.8x | 6.4x |
Wed, 13 Dec 2023 | HK$205.8b | HK$32.3b | HK$3.0b | 82.5x | 69x | 6.4x |
Fri, 10 Nov 2023 | HK$272.7b | HK$30.1b | HK$2.7b | 48.2x | 101.9x | 9.1x |
Sun, 08 Oct 2023 | HK$236.4b | HK$30.2b | HK$2.7b | 41.7x | 88.3x | 7.8x |
Tue, 05 Sep 2023 | HK$239.0b | HK$30.3b | HK$2.7b | 42.7x | 88.7x | 7.9x |
Thu, 03 Aug 2023 | HK$236.3b | HK$28.4b | HK$2.7b | 22.7x | 86.5x | 8.3x |
Sat, 01 Jul 2023 | HK$204.3b | HK$28.3b | HK$2.7b | 20.2x | 75.9x | 7.2x |
Mon, 29 May 2023 | HK$229.1b | HK$28.9b | HK$2.8b | 22.6x | 81.4x | 7.9x |
Wed, 26 Apr 2023 | HK$246.9b | HK$29.4b | HK$2.9b | 24.7x | 84.7x | 8.4x |
Fri, 24 Mar 2023 | HK$264.1b | HK$26.6b | HK$2.1b | 23.6x | 125.3x | 9.9x |
Sun, 19 Feb 2023 | HK$296.3b | HK$26.4b | HK$2.1b | 25.2x | 143x | 11.2x |
Tue, 17 Jan 2023 | HK$383.1b | HK$26.7b | HK$2.2b | 31.8x | 176.9x | 14.3x |
Thu, 15 Dec 2022 | HK$273.3b | HK$25.9b | HK$2.0b | 28.4x | 136.8x | 10.5x |
Sat, 12 Nov 2022 | HK$270.9b | HK$25.5b | HK$1.8b | 23.2x | 147x | 10.6x |
Mon, 10 Oct 2022 | HK$247.6b | HK$25.7b | HK$1.9b | 20.2x | 129.9x | 9.6x |
Wed, 07 Sep 2022 | HK$332.2b | HK$26.2b | HK$2.0b | 25.2x | 163.6x | 12.7x |
Fri, 05 Aug 2022 | HK$390.6b | HK$22.3b | HK$2.0b | 11.7x | 191.3x | 17.5x |
Sun, 03 Jul 2022 | HK$376.3b | HK$22.4b | HK$2.1b | 15.4x | 180.9x | 16.8x |
Tue, 31 May 2022 | HK$296.2b | HK$22.4b | HK$2.1b | 13.4x | 142.3x | 13.2x |
Thu, 28 Apr 2022 | HK$286.7b | HK$22.8b | HK$2.2b | 13x | 130.9x | 12.6x |
Sat, 26 Mar 2022 | HK$335.2b | HK$21.9b | HK$2.2b | 20.8x | 149x | 15.3x |
149x
How does Hong Kong Clinical Research and Equipment compare with similar industries?
HK Market | 2.45% | |
Healthcare | 3.89% | |
Life Sciences | 8.56% | |
Clinical Research and Equipment | 8.56% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
2269 WuXi Biologics (Cayman) | HK$27.95 | 16.0% +HK$15.8b | 100.8% | PE40.5x | |
2268 WuXi XDC Cayman | HK$45.00 | 26.9% +HK$11.4b | 168.8% | PE84.4x | |
1873 Viva Biotech Holdings | HK$1.87 | 24.7% +HK$781.5m | 266.7% | PS1.8x | |
2228 XtalPi Holdings | HK$6.76 | 1.2% +HK$272.5m | n/a | PS108.7x | |
1521 Frontage Holdings | HK$1.15 | 10.6% +HK$222.6m | -24.3% | PE49.1x |